Eron Joseph J
Department of Internal Medicine, University of North Carolina School of Medicine, 130 Mason Farm Road, Chapel Hill, NC 27599, USA.
J Infect Dis. 2008 May 15;197 Suppl 3:S261-71. doi: 10.1086/533418.
The management of patients receiving therapy for human immunodeficiency virus infection has improved in recent years owing to factors such as new classes of antiretroviral drugs, new agents in existing classes, and reduced resistance rates when chronically infected patients begin treatment with preferred regimens. Transmitted resistance variants in approximately 10% of treatment-naive patients underline the need for pretreatment resistance testing, to improve rates of virologic efficacy. Structured treatment interruptions to reduce drug exposure and toxicity should not be used outside well-controlled research studies, since this practice has been associated with increased rates of death and disease progression.
近年来，由于新的抗逆转录病毒药物类别、现有类别中的新药物以及慢性感染患者开始采用首选方案治疗时耐药率降低等因素，接受人类免疫缺陷病毒感染治疗的患者管理情况有所改善。约10%初治患者中存在传播耐药变异，这突出了进行治疗前耐药检测的必要性，以提高病毒学疗效。为减少药物暴露和毒性而进行的结构化治疗中断不应在严格控制的研究之外使用，因为这种做法与死亡率和疾病进展率增加有关。
